Forbion’s New Fund
This article was originally published in Start Up
Executive Summary
Dutch venture capital firm, Forbion Capital Partners, has launched a new €92 milion ($116 million) life science fund to invest in 12 to 15 new companies. This is first close for the new fund called Forbion Capital Fund III, en route to a target of €150 to €200 million.
You may also be interested in...
Medtech: Assessing Potential Return On Investment
Medtech entrepreneurs and investors are awakening to a new reality in venture funding, where exit times are lengthening and returns on investment are falling short. At the recent IN3 meeting in Dublin, a panel of medtech investors discussed how they are adapting their investment strategies to this changing landscape.
Finance Watch: Karuna, Cerevel And Others Benefit From Improving Biotech Sentiment
Good news in the biopharma industry and the US economy gave public drug developers the boost they needed to raise cash, including Karuna’s $750m offering. Private company financings slowed during the second week of August, but Prellis and Vector BioPharma raised venture capital.
Medtronic Recalls Cardiac Defibrillators Due To Reduced Shock Potential
The device giant is recalling Cobalt and Crome defibrillators because they may deliver weaker shocks than intended.